These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18039860)

  • 1. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice.
    Matijasevic Z; Steinman HA; Hoover K; Jones SN
    Mol Cell Biol; 2008 Feb; 28(4):1265-73. PubMed ID: 18039860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MdmX regulates transformation and chromosomal stability in p53-deficient cells.
    Matijasevic Z; Krzywicka-Racka A; Sluder G; Jones SN
    Cell Cycle; 2008 Oct; 7(19):2967-73. PubMed ID: 18818521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells.
    Matijasevic Z; Krzywicka-Racka A; Sluder G; Gallant J; Jones SN
    Oncogenesis; 2016 Oct; 5(10):e262. PubMed ID: 27694836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.
    Zhang Y; Zeng SX; Hao Q; Lu H
    Dev Biol; 2017 Mar; 423(1):34-45. PubMed ID: 28118981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
    Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
    Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis.
    Huang Q; Chen L; Yang L; Xie X; Gan L; Cleveland JL; Chen J
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3368-E3377. PubMed ID: 29581299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.
    Jones SN; Sands AT; Hancock AR; Vogel H; Donehower LA; Linke SP; Wahl GM; Bradley A
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14106-11. PubMed ID: 8943068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
    Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
    J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles and regulation of MDM2 and MDMX: it is not just about p53.
    Klein AM; de Queiroz RM; Venkatesh D; Prives C
    Genes Dev; 2021 May; 35(9-10):575-601. PubMed ID: 33888565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.
    Lenos K; de Lange J; Teunisse AF; Lodder K; Verlaan-de Vries M; Wiercinska E; van der Burg MJ; Szuhai K; Jochemsen AG
    Mol Cancer; 2011 Sep; 10():111. PubMed ID: 21910853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
    Tian H; Tackmann NR; Jin A; Zheng J; Zhang Y
    J Biol Chem; 2017 Dec; 292(52):21614-21622. PubMed ID: 29123033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.
    Zhang Y; Zhang X; Lu H
    Dev Biol; 2014 Dec; 396(1):19-30. PubMed ID: 25263199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.
    Marine JC; Jochemsen AG
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27371671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Roles of MDM2 and MDMX in Cancer.
    Karni-Schmidt O; Lokshin M; Prives C
    Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.
    Jin Y; Zeng SX; Sun XX; Lee H; Blattner C; Xiao Z; Lu H
    Mol Cell Biol; 2008 Feb; 28(4):1218-29. PubMed ID: 18086887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.
    Huang L; Yan Z; Liao X; Li Y; Yang J; Wang ZG; Zuo Y; Kawai H; Shadfan M; Ganapathy S; Yuan ZM
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12001-6. PubMed ID: 21730163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mdmx is a negative regulator of p53 activity in vivo.
    Finch RA; Donoviel DB; Potter D; Shi M; Fan A; Freed DD; Wang CY; Zambrowicz BP; Ramirez-Solis R; Sands AT; Zhang N
    Cancer Res; 2002 Jun; 62(11):3221-5. PubMed ID: 12036937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response.
    Zhang X; Lin L; Guo H; Yang J; Jones SN; Jochemsen A; Lu X
    Cancer Res; 2009 Oct; 69(20):7960-8. PubMed ID: 19808970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.